Alto Neuroscience, Inc. Other Comprehensive Income (Loss), Net of Tax
Alto Neuroscience, Inc. (ANRO) reported Other Comprehensive Income (Loss), Net of Tax of -$27.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-12
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$27.63M.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$26.25M.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was -$16.17M.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$14.20M.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was -$63.12M.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was -$61.45M.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was -$36.34M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$27.63M 10-Q · filed 2026-08-12 | -$53.88M 10-Q · filed 2026-08-12 | -$70.05M derived: sum of 3 quarters · filed 2026-08-12 | -$84.25M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$26.25M 10-Q · filed 2026-05-13 | -$42.42M derived: sum of 2 quarters · filed 2026-05-13 | -$56.62M derived: sum of 3 quarters · filed 2026-05-13 | -$74.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$16.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$30.37M derived: sum of 2 quarters · filed 2026-03-16 | -$48.06M derived: sum of 3 quarters · filed 2026-08-12 | -$63.12M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$14.20M 10-Q · filed 2025-11-12 | -$31.89M derived: sum of 2 quarters · filed 2026-08-12 | -$46.94M 10-Q · filed 2025-11-12 | -$62.15M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$17.69M 10-Q · filed 2026-08-12 | -$32.74M 10-Q · filed 2026-08-12 | -$47.95M derived: sum of 3 quarters · filed 2026-08-12 | -$64.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$15.05M 10-Q · filed 2026-05-13 | -$30.26M derived: sum of 2 quarters · filed 2026-05-13 | -$47.05M derived: sum of 3 quarters · filed 2026-05-13 | -$63.09M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$15.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$32.00M derived: sum of 2 quarters · filed 2026-03-16 | -$48.03M derived: sum of 3 quarters · filed 2026-03-16 | -$61.45M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$16.79M 10-Q · filed 2025-11-12 | -$32.82M derived: sum of 2 quarters · filed 2025-11-12 | -$46.25M 10-Q · filed 2025-11-12 | -$57.46M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$16.04M 10-Q · filed 2025-08-13 | -$29.46M 10-Q · filed 2025-08-13 | -$40.67M derived: sum of 3 quarters · filed 2025-08-13 | -$49.82M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$13.42M 10-Q · filed 2025-05-14 | -$24.63M derived: sum of 2 quarters · filed 2025-05-14 | -$33.78M derived: sum of 3 quarters · filed 2025-05-14 | -$42.46M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$11.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$20.36M derived: sum of 2 quarters · filed 2025-03-20 | -$29.04M derived: sum of 3 quarters · filed 2025-03-20 | -$36.34M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$9.15M 10-Q · filed 2024-11-12 | -$17.82M derived: sum of 2 quarters · filed 2024-11-12 | -$25.13M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$8.67M 10-Q · filed 2024-08-13 | -$15.98M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$7.30M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |